Cellular therapy for the treatment of solid tumors. (February 2021)

• Record Type: Journal Article
• Authors: Grimes, Joseph M.; Carvajal, Richard D.; Muranski, Pawel
• Is Part Of: Transfusion and apheresis science. Volume 60:Number 1(2021)
• Publication Date: 2021-02
• Subjects: Adoptive cellular therapy -- Tumor infiltrating lymphocytes -- CAR T cells -- TCR T cells -- Solid tumors; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2021.103056
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: Adoptive cellular therapy (ACT) is a form of cancer immunotherapy in which lymphocytes are removed from patient blood or tumor samples, expanded and/or genetically modified to improve tumor-fighting capabilities, and infused back into the patient. The main forms of ACT include tumor infiltrating lymphocytes (TILs), engineered T cell receptor (TCR) T cells, and chimeric antigen receptor (CAR) T cells. While ACT has had success in hematological malignancies, particularly in B cell lymphomas targeted with CAR T cells, these favorable outcomes have yet to be replicated in solid tumors. Appropriate solid tumor target antigens are difficult to identify for ACT. Trafficking to tumor sites and infiltrating solid tumor burdens remains a problem for ACT cells. Persistence of ACT cells, which is important in creating a durable response, is also a major challenge, partly attributed to the formidable microtumor environment conditions. The costly and time-intensive manufacturing process for ACT is also an obstacle to widespread adoption. In this review, we discuss the challenges of ACT therapy in the treatment of solid tumors and explore the ongoing efforts to improve this immunotherapy approach in non-hematological malignancies.